[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.12.79. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
October 2018

Bridging the Critical Divide in Pain Management Guidelines From the CDC, NCCN, and ASCO for Cancer Survivors

Author Affiliations
  • 1Department of Biobehavioral Health Sciences, NewCourtland Center for Transitions and Health, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia
  • 2Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Oncol. 2018;4(10):1323-1324. doi:10.1001/jamaoncol.2018.1574

One of the most conspicuous omissions in clinical oncology is the failure to generate accumulated empirical evidence about long-term opioid therapy in patients with persistent cancer or treatment-related pain. In response to the Centers for Disease Control and Prevention (CDC) opioid guideline for chronic pain,1 the American Society of Clinical Oncology (ASCO) noted that, despite the existence of multiple guidelines for pain management, evidence is lacking in many aspects of opioid use and studies on long-term opioid therapy in patients with cancer are sorely lacking.2 For instance, most trials that evaluate the outcomes of opioid therapy, such as pain, function, and quality of life, are 6 weeks or shorter and the CDC opioid guideline authors found no studies that investigated the effectiveness of opioid therapy long-term.1 This is despite the fact that long-term opioid therapy is prevalent among cancer survivors compared with age- and sex-matched controls, and, based on recent data, opioid therapy may continue for months to years after the initial diagnosis of cancer.3

×